• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why ZIM Integrated Shipping Services Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket

    1/29/24 7:56:17 AM ET
    $ACON
    $AEVA
    $BJDX
    $CPHI
    Medical Specialities
    Health Care
    Auto Parts:O.E.M.
    Consumer Discretionary
    Get the next $ACON alert in real time by email

    ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) shares rose sharply in today's pre-market trading after Jefferies upgraded the stock from Hold to Buy and raised its price target from $14 to $20.

    ZIM Integrated Shipping Services shares climbed 9.2% to $14.72 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • NovaBay Pharmaceuticals, Inc. (NYSE:NBY) gained 71.3% to $0.2810 in pre-market trading after gaining around 8% on Friday. NovaBay Pharmaceuticals and Sonoma Pharmaceuticals recently agreed to market Avenova-branded products in the European Union.
    • Spectral AI, Inc. (NASDAQ:MDAI) gained 33.9% to $3.63 in pre-market trading after gaining more than 35% on Friday. BTIG analyst Ryan Zimmerman recently initiated coverage on Spectral AI with a Buy rating and announced a price target of $4.
    • TuanChe Limited (NASDAQ:TC) shares jumped 31.4% to $3.10 in pre-market trading after jumping more than 10% on Friday.
    • Jianzhi Education Technology Group Company Limited (NASDAQ:JZ) gained 24.1% to $0.7818 in pre-market trading.
    • 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) surged 17.7% to $0.5884 in pre-market trading. 60 Degrees Pharmaceuticals recently announced that, following a Type C meeting held on Jan. 17, 2024, with the FDA, the company will move forward with a pivotal clinical study of tafenoquine in hospitalized babesiosis patients in the U.S.
    • Bluejay Diagnostics, Inc. (NASDAQ:BJDX) shares rose 16.7% to $0.90 in pre-market trading.
    • Palisade Bio, Inc. (NASDAQ:PALI) shares rose 16.4% to $0.61 in pre-market trading. Palisade Bio requested to withdraw the registration statement and may consider subsequent private offerings instead.
    • IM Cannabis Corp. (NASDAQ:IMCC) shares gained 16.3% to $0.3820 in pre-market trading after surging around 60% on Friday.
    • China Pharma Holdings, Inc. (NYSE:CPHI) shares gained 12.3% to $0.1051 in pre-market trading.

     

    Losers

    • Panbela Therapeutics, Inc. (NASDAQ:PBLA) shares dipped 35.6% to $2.75 in pre-market trading after jumping 31% on Friday. Panbela Therapeutics recently said it has reached 50% enrollment in ASPIRE trial of ivospemin plus gemcitabine and nab-paclitaxel combo in first-line treatment of metastatic pancreatic cancer.
    • Aeva Technologies, Inc. (NYSE:AEVA) shares fell 35.6% to $0.55 in pre-market trading after falling around 4% on Friday.
    • Aclarion, Inc. (NASDAQ:ACON) shares fell 28.2% to $2.04 in pre-market trading after surging 52% on Friday.
    • Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) fell 18.3% to $24.06 in pre-market trading. Corbus Pharmaceuticals shares jumped 249% on Friday after the company announced data from the first-in-human clinical study of CRB-701 is being presented as a poster by its development partner CSPC Pharmaceutical at ASCO GU 2024.
    • Planet Green Holdings Corp. (NYSE:PLAG) fell 17.7% to $0.34 after dipping 8% on Friday.
    • Inspire Veterinary Partners, Inc. (NASDAQ:IVP) shares declined 17.7% to $0.1840 in pre-market trading after surging 17% on Friday.
    • Globavend Holdings Limited (NASDAQ:GVH) shares fell 17% to $0.7890 in pre-market trading.
    • SMX (Security Matters) Public Limited Company (NASDAQ:SMX) declined 16.1% to $0.3610 in pre-market trading after gaining around 83% on Friday.
    • Cyngn Inc. (NASDAQ:CYN) shares declined 12.7% to $0.2322 in pre-market trading after gaining around 24% on Friday.
    • Koninklijke Philips N.V. (NYSE:PHG) shares dipped 5.6% to $21.48 in pre-market trading after the company reported fourth-quarter results and agreed with the US Department of Justice (DOJ), representing the FDA, on terms of consent decree focused on Philips Respironics in the US.

    Now Read This: Nucor, Super Micro Computer And 3 Stocks To Watch Heading Into Monday

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $AEVA
    $BJDX
    $CPHI

    CompanyDatePrice TargetRatingAnalyst
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    12/17/2025Sector Perform
    RBC Capital Mkts
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/30/2025$28.00Buy
    B. Riley Securities
    ZIM Integrated Shipping Services Ltd.
    $ZIM
    5/20/2025$20.00Buy → Neutral
    Clarksons Platou
    Aeva Technologies Inc.
    $AEVA
    4/1/2025$9.50Buy
    Canaccord Genuity
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    2/28/2025Outperform
    William Blair
    More analyst ratings

    $ACON
    $AEVA
    $BJDX
    $CPHI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on Palisade Bio with a new price target

    B. Riley Securities initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    1/9/26 9:07:04 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Palisade Bio with a new price target

    Piper Sandler initiated coverage of Palisade Bio with a rating of Overweight and set a new price target of $25.00

    12/29/25 7:10:24 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $AEVA
    $BJDX
    $CPHI
    Leadership Updates

    Live Leadership Updates

    View All

    Cyngn Adds Former Lyft Exec, Ran Makavy, to Board

    Mr. Makavy led growth at Lyft and later ran its core platform through the 2019 IPO. He also founded Snaptu, which was acquired by Facebook in 2011.MOUNTAIN VIEW, Calif., Feb. 25, 2026 /PRNewswire/ -- Cyngn (NASDAQ:CYN) today announced the appointment of Ran Makavy to its Board of Directors. He brings senior growth and platform leadership experience from Lyft and Facebook, where he helped scale large technology businesses through high-growth phases. At Lyft, Makavy built the growth team which was responsible for getting more drivers and riders to use Lyft and getting them to use

    2/25/26 7:05:00 AM ET
    $CYN
    EDP Services
    Technology

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Spectral AI Names Vincent S. Capone as Chief Executive Officer

    DALLAS, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the Company's Board of Directors has appointed Vincent S. Capone as Chief Executive Officer of the Company, effective February 9, 2026. The appointment of Mr. Capone, who currently serves as the Company's Chief Financial Officer and General Counsel, comes as Spectral AI transitions towards commercialization of its proprietary, non-invasive, AI-driven burn wound assessment device – the DeepView® System. "Vince brings a unique set

    2/10/26 8:30:00 AM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    $ACON
    $AEVA
    $BJDX
    $CPHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

    FDA has until May 25, 2026 to object to the notification, after which the Company will be free to market its proposed dietary supplement containing Australian Chestnut ExtractCompany has signed an option agreement with Florida State University (FSU) to license a capsule formulation, expanding on its recent exercise of a license option for large-scale production WASHINGTON, March 18, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced it submitted a New Dietary Ingredient Notification (NDIN) to the U.S. Food and Drug Admi

    3/18/26 8:01:00 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit

    NORWOOD, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused promising new therapies in oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a moderated panel discussion at the BMO 2026 Metabolic Health Summit, to be held in New York, NY, on Tuesday, March 24, 2026. Corbus is advancing CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. CRB-913 demonstrated potent, rapid weight loss and favorable GI tolerability in a 14-day Phase 1a SAD/MAD study, suggesting this drug could provide a novel long

    3/18/26 8:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyngn Inc. Announces Closing of $9.65 Million Registered Direct Offering, Priced at the Market Under Nasdaq Rules

    MOUNTAIN VIEW, Calif., March 17, 2026 /PRNewswire/ -- Cyngn Inc. (NASDAQ:CYN) today announced the closing of its previously announced registered direct offering for the purchase and sale of approximately $9.65 million of shares of Common Stock and pre-funded warrants at a price of $1.93 per share of Common Stock. A single institutional investor acquired greater than ninety percent of the offering, with a high-net-worth individual purchasing the remaining percent. The entire transaction was priced at the market under Nasdaq rules. The offering consisted of the sale of 5,000,000 s

    3/17/26 10:48:00 AM ET
    $CYN
    EDP Services
    Technology

    $ACON
    $AEVA
    $BJDX
    $CPHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Odedra Anita

    3 - ZIM Integrated Shipping Services Ltd. (0001654126) (Issuer)

    3/17/26 7:42:21 AM ET
    $ZIM
    Marine Transportation
    Consumer Discretionary

    SEC Form 3 filed by new insider Metanes Abdallah

    3 - ZIM Integrated Shipping Services Ltd. (0001654126) (Issuer)

    3/17/26 6:49:46 AM ET
    $ZIM
    Marine Transportation
    Consumer Discretionary

    SEC Form 3 filed by new insider Meyer-Gloeckner Birger Johannes

    3 - ZIM Integrated Shipping Services Ltd. (0001654126) (Issuer)

    3/16/26 11:23:43 AM ET
    $ZIM
    Marine Transportation
    Consumer Discretionary

    $ACON
    $AEVA
    $BJDX
    $CPHI
    SEC Filings

    View All

    Bluejay Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    3/17/26 5:30:11 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    SEC Form S-3 filed by Planet Green Holdings Corp.

    S-3 - Planet Green Holdings Corp. (0001117057) (Filer)

    3/17/26 5:02:13 PM ET
    $PLAG
    Packaged Foods
    Consumer Staples

    Cyngn Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Cyngn Inc. (0001874097) (Filer)

    3/17/26 4:30:26 PM ET
    $CYN
    EDP Services
    Technology

    $ACON
    $AEVA
    $BJDX
    $CPHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Dow Geoffrey S bought $7,759 worth of shares (9,670 units at $0.80), increasing direct ownership by 19% to 59,618 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/16/25 5:41:35 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AEVA
    $BJDX
    $CPHI
    Financials

    Live finance-specific insights

    View All

    Spectral AI Schedules 2025 Fourth Quarter and Full Year Financial Results and Conference Call

    DALLAS, March 10, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2025 on Tuesday, March 24, 2026 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time that day to discuss the results. Investors interested in participating in the live call can dial: 833-890-6620 – U.S.412-564-3789 – International A simultaneous webcast of the call may be access

    3/10/26 8:30:00 AM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    ZIM Reports Financial Results for the Fourth Quarter and the Full Year of 2025

    Reported Full Year Revenues of $6.90 Billion, Net Income of $481 Million1, Adjusted EBITDA2 of $2.17 Billion and Adjusted EBIT2 of $885 Million3Generated Full Year Adjusted EBITDA and Adjusted EBIT Margins2 of 31% and 13%, Respectively Declared Q4 2025 Dividend of Approximately $106 Million, or $0.88 per Share, Representing, Together with Previous Dividends Distributed on Account of 2025 Results, Approximately 50% of the Full Year 2025 Net Income Dividends to Total Approximately $5.8 Billion Over Last Five Years—More Than 25 Times the Amount Raised at IPO in January 2021HAIFA, Israel, March 9, 2026 /PRNewswire/ -- ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) ("ZIM" or the "Company"), a g

    3/9/26 7:00:00 AM ET
    $ZIM
    Marine Transportation
    Consumer Discretionary

    Cyngn Announces Date for 2025 Fourth Quarter and Year-End Financial Results

    MOUNTAIN VIEW, Calif., March 5, 2026 /PRNewswire/ -- Cyngn (NASDAQ:CYN) will announce its 2025 fourth quarter and year-end financial results for the period ended December 31, 2025, on Wednesday, March 25, 2026, after the close of market. The financial results will be available on the Cyngn website under "News & Events" at https://investors.cyngn.com/.  The Company will not host an earnings call.About CyngnCyngn develops and deploys autonomous vehicle technology for industrial organizations like manufacturers and logistics companies. The Company addresses significant challenges f

    3/5/26 7:05:00 AM ET
    $CYN
    EDP Services
    Technology

    $ACON
    $AEVA
    $BJDX
    $CPHI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Globavend Holdings Limited

    SC 13G - Globavend Holdings Ltd (0001978527) (Subject)

    11/20/24 4:36:45 PM ET
    $GVH
    Integrated Freight & Logistics
    Industrials

    Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 7:48:14 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 6:41:20 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care